Archer Materials Limited (ASX:AXE) Advances Biochip Technology
Progress on Biochip Technology
Archer Materials Limited (ASX: AXE) has made significant strides in the development of its Biochip technology, specifically designed for chronic kidney disease testing. The company has generated potassium sensing datasets and is refining the performance of its graphene field effect transistor (gFET) sensors.
Testing Enhancements
Recent tests have shown improvements in the operation and design of the gFET sensors. Archer has achieved better stability for the latest gFET devices through collaboration with its foundry partners. A new electrical conditioning procedure has resulted in a tenfold enhancement in voltage repeatability, crucial for accurate potassium measurements in blood tests.
Collaboration and Benchmarking
Archer has undertaken initial benchmarking of gFETs in partnership with RMIT University to validate their performance against other biosensor technologies. The results from these experiments are under analysis and will guide future developments.
Executive Comments
Greg English, Executive Chair of Archer Materials, stated, “The Archer team has made some important progress in bringing the Biochip to the feasibility stages and improving the accuracy for testing blood potassium levels for chronic kidney disease. These developments are key in the ultimate purpose of the Biochip, which is to bring the testing of chronic kidney disease into the home and therefore improve patient outcomes through better diagnosis and treatment.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.